BioStock: Final adjustments and validation take center stage at Prolight Diagnostics
Prolight Diagnostics continues its preparations to bring the Psyros platform to market. System optimization is ongoing, with the next key milestone being an “assay design freeze.” Once achieved, the company will proceed to internal verification and validation ahead of the pivotal clinical performance study. BioStock spoke with CEO Ulf Bladin to learn more about the progress.
Read the full article at biostock.se:
https://biostock.se/en/2025/11/slutjusteringar-och-validering-i-fokus-hos-prolight-diagnostics-2/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se